ETFs Black Diamond Therapeutics, Inc.

BDTX

US09203E1055

Biotechnology & Medical Research

Market Closed - Nasdaq 00:00:00 29/10/2026 +04			5-day change	1st Jan Change
1.830 ^USD	+4.57%		-12.02%	-24.69%

08-06	Black Diamond Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-29	Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) added to Russell 2000 Index	CI

ETFs positioned on Black Diamond Therapeutics, Inc.

Name	YTD change	Weight	AuM
DIMENSIONAL WORLD EQUITY ETF - USD	+13.44%	-	1,674 M€
EA BRIDGEWAY OMNI SMALL-CAP VALUE ETF - USD	+24.04%	0.03%	2,474 M€
FIDELITY ENHANCED SMALL CAP ETF - USD	+21.44%	0.03%	6,480 M€
ISHARES MICRO-CAP ETF - USD	+15.05%	0.02%	1,518 M€
FIDELITY ENHANCED U.S. ALL-CAP EQUITY ETF - USD	+13.95%	0.01%	18 M€
AVANTIS U.S. SMALL CAP EQUITY ETF - USD	+21.42%	0.01%	3,154 M€
INVESCO RAFI US 1500 SMALL-MID ETF - USD	+17.03%	0.01%	2,894 M€
INVESCO NASDAQ BIOTECHNOLOGY ETF - USD	+26.18%	0.01%	81 M€
ISHARES NASDAQ US BIOTECHNOLOGY UCITS ETF (D) - USD	+26.39%	0.01%	78 M€
ISHARES NASDAQ US BIOTECHNOLOGY UCITS ETF - USD	+26.87%	0.01%	1,079 M€
ISHARES BIOTECHNOLOGY ETF - USD	+28.19%	0.01%	9,953 M€
CI INVESCO RAFI GLOBAL SMALL-MID ETF - CAD	0.00%	0.01%	19 M€
STATE STREET SPDR RUSSELL 2000 U.S. SMALL CAP UCITS ETF - USD	+14.78%	0%	5,739 M€
CI INVESCO RAFI GLOBAL SMALL-MID ETF - USD	+10.08%	0%	0 M€
CI INVESCO RAFI GLOBAL SMALL-MID ETF - CAD HEDGED	0.00%	0%	3 M€
VANGUARD EXTENDED MARKET ETF - USD	+11.70%	0%	32,130 M€
DIMENSIONAL US CORE EQUITY 1 ETF - USD	+14.80%	0%	3,517 M€
LEUTHOLD CORE ETF - USD	+6.28%	0%	68 M€
VANGUARD MORNINGSTAR U.S. TOTAL MARKET INDEX ETF - CAD	+15.22%	0%	14,144 M€
VANGUARD MORNINGSTAR TOTAL STOCK MARKET ETF - USD	+13.09%	0%	692,025 M€
VANGUARD BALANCED ETF PORTFOLIO - CAD	+7.17%	0%	4,204 M€
VANGUARD ALL-EQUITY ETF PORTFOLIO - CAD	+15.36%	0%	12,086 M€
VANGUARD GROWTH ETF PORTFOLIO - CAD	+10.74%	0%	7,793 M€
UPAR ULTRA RISK PARITY ETF - USD	-0.45%	0%	59 M€
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD	+5.59%	0%	37 M€
ELM MARKET NAVIGATOR ETF - USD	+7.49%	0%	594 M€
VANGUARD CONSERVATIVE ETF PORTFOLIO - CAD	+3.64%	0%	688 M€
CAMBRIA TAX AWARE ETF - USD	+8.05%	0%	26 M€
ISHARES LIFEPATH TARGET DATE 2030 ETF - USD	+6.32%	0%	80 M€
DEFINED DURATION 20 ETF - USD	+11.37%	0%	19 M€
RPAR RISK PARITY ETF - USD	+0.93%	0%	580 M€
CI GLOBAL CORE PLUS EQUITY ETF - CAD	0.00%	0%	43 M€
VANGUARD CONSERVATIVE INCOME ETF PORTFOLIO - CAD	+0.19%	0%	184 M€
VANGUARD RETIREMENT INCOME ETF PORTFOLIO - CAD	+1.19%	0%	267 M€
CLEARSHARES OCIO ETF - DISTRIBUTING - USD	+8.69%	0%	176 M€
AB US EQUITY ETF - USD	+10.24%	0%	727 M€
DEFINED DURATION 5 ETF - USD	+0.48%	0%	18 M€
CAMBRIA GLOBAL EW ETF - USD	+8.66%	0%	146 M€
WARREN STREET GLOBAL EQUITY ETF - USD	+13.33%	-.--%	62 M€
CAMBRIA ENDOWMENT STYLE ETF - USD	+11.76%	-.--%	156 M€

1 2

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Companyâ€™s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.

Employees

Sector

Biotechnology & Medical Research

More about the company